DexCom (NASDAQ:DXCM) Upgraded to “Buy” by StockNews.com

DexCom (NASDAQ:DXCM) was upgraded by investment analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Wednesday.

Several other equities analysts also recently weighed in on DXCM. UBS Group raised their target price on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Royal Bank of Canada assumed coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 target price on the stock. Citigroup raised their price target on DexCom from $148.00 to $161.00 and gave the stock a “buy” rating in a research report on Wednesday, April 3rd. Raymond James upped their price objective on DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research report on Friday, April 26th. Finally, Canaccord Genuity Group increased their price objective on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research note on Friday, April 26th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $141.67.

DexCom Trading Up 1.3 %

NASDAQ:DXCM opened at $127.39 on Wednesday. DexCom has a 1 year low of $74.75 and a 1 year high of $142.00. The company has a debt-to-equity ratio of 1.08, a quick ratio of 2.53 and a current ratio of 2.90. The stock has a fifty day moving average price of $131.49 and a two-hundred day moving average price of $119.53. The stock has a market capitalization of $50.66 billion, a price-to-earnings ratio of 82.19, a PEG ratio of 2.11 and a beta of 1.20.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, April 25th. The medical device company reported $0.32 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. As a group, sell-side analysts anticipate that DexCom will post 1.78 earnings per share for the current fiscal year.

Insider Buying and Selling at DexCom

In related news, EVP Sadie Stern sold 20,321 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the sale, the executive vice president now owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, EVP Matthew Vincent Dolan sold 1,990 shares of the business’s stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $137.81, for a total transaction of $274,241.90. Following the transaction, the executive vice president now directly owns 42,377 shares of the company’s stock, valued at approximately $5,839,974.37. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 20,321 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $133.61, for a total transaction of $2,715,088.81. Following the completion of the sale, the executive vice president now directly owns 80,441 shares of the company’s stock, valued at approximately $10,747,722.01. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 189,375 shares of company stock valued at $25,530,859. Company insiders own 0.41% of the company’s stock.

Institutional Trading of DexCom

A number of hedge funds and other institutional investors have recently modified their holdings of DXCM. DSM Capital Partners LLC bought a new position in shares of DexCom during the fourth quarter worth about $28,000. Valley National Advisers Inc. lifted its holdings in DexCom by 73.0% during the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after buying an additional 103 shares during the last quarter. Riverview Trust Co acquired a new position in shares of DexCom in the 1st quarter worth approximately $32,000. MV Capital Management Inc. increased its holdings in shares of DexCom by 99.3% in the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 138 shares during the last quarter. Finally, Smithfield Trust Co raised its position in shares of DexCom by 103.1% during the 4th quarter. Smithfield Trust Co now owns 325 shares of the medical device company’s stock valued at $40,000 after acquiring an additional 165 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.